Hetq 200 Tablet contains Hydroxychloroquine 200 mg, an antimalarial agent with immunomodulatory properties. It is primarily indicated for the treatment and prevention of malaria caused by Plasmodium species. Additionally, Hetq 200 is utilized in the management of autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus, where it helps to reduce inflammation and modulate the immune response. Hydroxychloroquine acts by interfering with lysosomal activity and antigen presentation, thereby suppressing immune cell activation. The tablet should be taken orally, with or without food, as prescribed by a healthcare professional. Dosage and duration depend on the specific condition being treated, patient response, and tolerability. Common adverse effects include gastrointestinal disturbances, headache, dizziness, and skin rash. Rare but serious side effects may involve retinal toxicity, necessitating regular ophthalmologic monitoring during prolonged therapy. Caution is advised in patients with pre-existing retinal or visual field changes, cardiac conditions, or glucose-6-phosphate dehydrogenase deficiency. Hetq 200 should not be used in patients with known hypersensitivity to Hydroxychloroquine or related compounds. It is essential to adhere to prescribed dosing and consult a physician before initiating or discontinuing therapy to ensure safe and effective use.